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LETTER TO THE EDITOR
Copy-Number Variations and Human Disease
To the Editor: The comprehensive mapping of genomic
copy-number variations (CNVs) should allow for those
variants to be studied for their correlation with disease
phenotypes.1 One line of evidence that was advanced to
support potential implications of CNVs for human disease
was the overlap of CNVswith chromosomal loci harboring
genes known to very often cause well-characterizedmono-
genic illnesses from the OMIM database.1 But a general
concern arises from the list of CNVs that overlap rare dis-
ease genes reported in table 5 of the mapping study by
Wong et al.1 For instance, the BSCL2 gene fell within a
CNV region that had a frequency of 3 in 105 subjects. The
gene was noted by the authors to be causative for spinal
muscular atrophy, distal, type V (MIM 600794),1 and in-
deed two missense mutations in BSCL2 (MIM 606158.0013
and .0014) have been reported for that phenotype. How-
ever, 13 other missense mutations in that gene cause Ber-
ardinelli-Seip congenital generalized lipodystrophy (BSCL),
an extremely rare autosomal recessive disorder affecting
∼1 person in 10 million.2 Thus, the observed frequency
of ∼3% BSCL2-CNV heterozygotes seems high, given the
low prevalence of BSCL as ascertained clinically in the
general population. Conservative assumption of a BSCL2-
CNV frequency of 1% would predict a homozygote fre-
quency of a major CNV rearrangement of this region of
1 person in 40,000, a frequency that is much higher than
the observed prevalence of BSCL—or of any spinal mus-
cular atrophy subtype, for that matter—in the general
population. The same type of disparity between predicted
and observed prevalence appears to hold true for several
other genes causing very rare homozygous diseases that
lie within CNV loci,1 including SMA3 (MIM 253400) and
SMA4 (MIM 271150), which cause spinal muscular atro-
phy subtypes (CNVs seen in 60 of 105 samples), and GCK
(MIM 138979), which causes neonatal-onset diabetes
(CNVs seen in 10 of 105 samples). Obviously, CNVs in-
clude both duplications and deletions, and homozygosity
for a duplication-type CNV would not necessarily imply
the same pathogenic consequence as a deletion-type CNV
for an OMIM gene. Thus, calculations of predicted disease
frequency should be based on homozygosity for the subset
of deletion-type CNVs. But, because deletions would still
be expected to represent a sizable subset of CNVs for at
least a sizable subset of OMIM genes, the predicted disease
rate would still be much higher than the observed fre-
quency of the autosomal recessive disease phenotype in
the general population.
There may be some valid biological reasons for the ap-
parent disparities between the observed frequency of CNV
heterozygotes and the reported frequencies of the related
rare OMIM recessive diseases, including (1) inaccurate dis-
ease-frequency estimates in published reports that under-
estimate the actual frequency of the phenotype in the
general population (perhaps subtle or later-onset forms of
the phenotypes might be more prevalent in the general
population than has been generally recognized), (2) in-
compatibility of homozygosity for certain completely de-
leted genes with fetal viability, (3) derivation of CNV-fre-
quency estimates in nonrepresentative “normal control”
samples, and (4) rescue of the lost or altered function in
homozygotes for a CNV by another gene product. Alter-
natively, there may be systematic technical reasons for
potential disparities leading to overestimationof someCNV
frequencies. It would thus be important to validate those
CNVs with use of alternative technologies, such as quan-
titative PCR,3 and to expand the samples of normal control
subjects to determine whether homozygotes for those
CNVs exist among “healthy” controls. In addition, studies
within families, both healthy and diseased, might help to
clarify the potential pathogenicity of some of these CNVs.
The ﬁndings emphasize the fact that the excitement over
the biological reality of CNVs within clinical and research
samples should be tempered pending the development of
standards and independent wide-scale replications, pos-
sibly with use of a variety of detection methods.
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